SELLAS Life Sciences Group, Inc. Annual Report - How They Did This Year

Hey there! Thinking about investing in SELLAS Life Sciences? This guide explains their performance over the past year (ending December 31, 2025). We'll break down the important stuff in plain English. You don't need a finance degree to understand it.

1. What does this company do and how did they perform this year? SELLAS Life Sciences Group, Inc. is a drug development company in advanced stages. They create new cancer treatments, like immunotherapies and targeted therapies. They focus on two main drug candidates: galinpepimut-S (GPS) and GFH009. GPS is a cancer immunotherapy made from peptides. It targets the WT1 protein, found in many blood and solid cancers. Their main GPS program treats Acute Myeloid Leukemia (AML). This is for AML patients in second complete remission. GFH009 is a very specific small molecule. It inhibits CDK9, a protein that helps cancer cells grow. They develop it for various blood and solid tumors.

   In the fiscal year ending December 31, 2025, SELLAS advanced its drug pipeline. They made progress by enrolling patients and developing their main programs. SELLAS trades on Nasdaq under the ticker SLS. As of June 30, 2025, their public shares (public float) were worth about $219.1 million. They also had about 179.6 million shares outstanding on March 18, 2026. SELLAS is a "smaller reporting company" and a "non-accelerated filer." This means they are a smaller public company. They have fewer reporting requirements.

2. Financial performance - revenue, profit, growth metrics In 2025, SELLAS earned only about $0.5 million in revenue. This came mostly from grants or partnerships. This was a small increase from $0.3 million in 2024. It shows they are still early in selling products. Like many drug development companies, SELLAS lost about $65.2 million in 2025. They lost $58.9 million in 2024. Higher research and development (R&D) costs caused this bigger loss. They advanced their clinical trials.

   R&D expenses were about $48.5 million in 2025. This was up from $42.1 million in 2024. This reflects higher clinical trial costs for GPS and GFH009. Personnel and manufacturing expenses also rose. General and administrative expenses were about $16.7 million in 2025. This compares to $15.8 million in 2024. This was mainly due to higher professional fees and public company costs. The company's financial results show its continued investment in new drugs. They spend a lot on R&D. This aims to move their drug candidates through trials. The goal is potential regulatory approval.

3. Major wins and challenges this year Every company has its ups and downs. SELLAS focused on advancing its main drug candidate, galinpepimut-S (GPS). They continued enrolling patients in the pivotal Phase 3 REGAL study for GPS. This study is for AML patients in second complete remission. This study is a critical step for potential regulatory approval. The main goal is overall survival. Successful enrollment and progress toward data are key milestones.

   Another big step was the ongoing Phase 1/2 clinical trial for GFH009. This is their very specific CDK9 inhibitor. This trial tests GFH009 in patients with relapsed or refractory blood cancers. Early data from the dose escalation phase is crucial. It helps determine the drug's safety, tolerability, and early effectiveness. Positive results from these early trials are essential. They help attract partners and secure future funding.

   Challenges included the large amount of money needed for these advanced clinical trials. This often requires more fundraising. Drug development always carries risks. These include potential delays in patient enrollment or unexpected trial outcomes. These remained significant hurdles.

4. Financial health - cash, debt, liquidity This is about how strong their bank account looks. As of December 31, 2025, SELLAS had about $38.5 million in cash. This was down from $55.1 million at December 31, 2024. This decrease shows the significant cash used for R&D and daily operations. The company's working capital deficit was about $12.3 million at year-end 2025. This means their short-term bills were more than their short-term assets.

   SELLAS had very little long-term debt at year-end 2025. They mainly used stock sales to fund operations. Based on their current plans, their cash should fund operations into the third quarter of 2026. This means they will need to raise more money. This is necessary to continue operations and finish their drug programs. "Liquidity" means how easily they can turn assets into cash. For SELLAS, this depends on selling more stock or finding partners. The company's ability to keep operating depends on getting more funding.

5. Key risks that could hurt the stock price No investment is without risk. Like most drug development companies, SELLAS faces many risks. These could impact your investment. A main risk is the outcome of their clinical trials. The pivotal Phase 3 REGAL study for GPS is especially important. Drug candidates, even in late stages, often fail. They might not show effectiveness or safety. This would severely impact the company's value. Negative results or delays for GPS would significantly hurt the stock price.

   There's also the challenge of developing, making, and selling products if approved. This involves complex regulatory steps. They need to build manufacturing and sales teams. They also need to raise enough money to keep operations going.

Ultimately, investing in SELLAS means weighing the potential of their drug candidates against the significant financial needs and inherent risks of drug development.